Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

407 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
Susceptibility to exacerbation in chronic obstructive pulmonary disease.
Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Hurst JR, et al. Among authors: wedzicha ja. N Engl J Med. 2010 Sep 16;363(12):1128-38. doi: 10.1056/NEJMoa0909883. N Engl J Med. 2010. PMID: 20843247 Free article.
Can patients with COPD self-manage?
Wedzicha JA, Vestbo J. Wedzicha JA, et al. Lancet. 2012 Aug 18;380(9842):624-5. doi: 10.1016/S0140-6736(12)61339-7. Lancet. 2012. PMID: 22901870 No abstract available.
Factors associated with change in exacerbation frequency in COPD.
Donaldson GC, Müllerova H, Locantore N, Hurst JR, Calverley PM, Vestbo J, Anzueto A, Wedzicha JA. Donaldson GC, et al. Among authors: wedzicha ja. Respir Res. 2013 Jul 30;14(1):79. doi: 10.1186/1465-9921-14-79. Respir Res. 2013. PMID: 23899210 Free PMC article. Clinical Trial.
Minimal clinically important differences in pharmacological trials.
Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Jones PW, et al. Among authors: wedzicha ja. Am J Respir Crit Care Med. 2014 Feb 1;189(3):250-5. doi: 10.1164/rccm.201310-1863PP. Am J Respir Crit Care Med. 2014. PMID: 24383418 Review.
Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study.
Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Wedzicha JA, et al. Lancet Respir Med. 2013 May;1(3):199-209. doi: 10.1016/S2213-2600(13)70052-3. Epub 2013 Apr 23. Lancet Respir Med. 2013. PMID: 24429126 Clinical Trial.
QVA149 versus glycopyrronium for COPD - authors' reply.
Wedzicha JA, Decramer M, Ficker JH, Niewoehner DE, Sandström T, Taylor AF, D'Andrea P, Arrasate C, Chen H, Banerji D. Wedzicha JA, et al. Lancet Respir Med. 2013 Jul;1(5):e23. doi: 10.1016/S2213-2600(13)70104-8. Epub 2013 Jul 8. Lancet Respir Med. 2013. PMID: 24429211 No abstract available.
407 results